Recovery of vancomycin-resistant gram-positive cocci from pediatric liver transplant recipients - PubMed (original) (raw)
Recovery of vancomycin-resistant gram-positive cocci from pediatric liver transplant recipients
M Green et al. J Clin Microbiol. 1991 Nov.
Abstract
Between November 1988 and October 1989, 49 first-time pediatric liver transplant recipients at the Children's Hospital of Pittsburgh were prospectively monitored for the presence of stool colonization and the development of disease caused by vancomycin-resistant gram-positive cocci (VRGPC). Quantitative stool culturing was done on a weekly basis, and cultures were planted onto a selective medium for VRGPC. Isolates for which the MIC was greater than or equal to 8 were considered resistant to vancomycin. Patients were monitored clinically for the development of infection, and their charts were systematically reviewed for the use of antibiotics. Eighty-six isolates were recovered from 36 of the 49 patients. Enterococcal species were isolated from 31 patients and included Enterococcus gallinarum (n = 28), E. casseliflavus (n = 14), E. faecium (n = 9), E. faecalis (n = 2), E. mundtii (n = 2), and E. durans (n = 1). Stool colonization with vancomycin-resistant enterococci was noted to increase steadily during the first month after transplantation. Only 9 of 31 patients demonstrated clearance of these organisms in serial repeat cultures. Additional isolates of VRGPC included Lactobacillus confusus (n = 13), Lactobacillus spp. (n = 12), and Pediococcus pentosaceus (n = 4). Infection due to VRGPC developed in three patients: a urinary tract infection in two and peritonitis in one. E. faecium was the pathogen in each of these cases. The ranges of MICs of vancomycin were 8 to 32 micrograms/ml for all enterococcal isolates and greater than 128 micrograms/ml for Lactobacillus and Pediococcus isolates. All Lactobacillus and Pediococcus isolates were resistant to teicoplanin, although they were susceptible to daptomycin. All other isolates were susceptible to both teicoplanin and daptomycin. This study demonstrates that stool colonization with VRGPC may be a common and early finding among pediatric liver transplant recipients. However, infection appears to be uncommon.
Similar articles
- Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. Biedenbach DJ, et al. Int J Antimicrob Agents. 2007 Aug;30(2):143-9. doi: 10.1016/j.ijantimicag.2007.03.015. Epub 2007 May 24. Int J Antimicrob Agents. 2007. PMID: 17531446 - Recovery of vancomycin-resistant gram-positive cocci from children.
Green M, Wadowsky RM, Barbadora K. Green M, et al. J Clin Microbiol. 1990 Mar;28(3):484-8. doi: 10.1128/jcm.28.3.484-488.1990. J Clin Microbiol. 1990. PMID: 2108993 Free PMC article. - Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS. Pfaller MA, et al. J Antimicrob Chemother. 2018 Oct 1;73(10):2748-2756. doi: 10.1093/jac/dky235. J Antimicrob Chemother. 2018. PMID: 29982565 - Treatment options for vancomycin-resistant enterococcal infections.
Linden PK. Linden PK. Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002. Drugs. 2002. PMID: 11827558 Review. - [Bacteremia caused by Enterococcus gallinarum with a high level of glycopeptide resistance: 1st documented cases in Argentina].
Togneri A, Lopardo H, Corso A. Togneri A, et al. Rev Argent Microbiol. 2003 Apr-Jun;35(2):96-9. Rev Argent Microbiol. 2003. PMID: 12920991 Review. Spanish.
Cited by
- Non-faecium non-faecalis enterococci: a review of clinical manifestations, virulence factors, and antimicrobial resistance.
Mullally CA, Fahriani M, Mowlaboccus S, Coombs GW. Mullally CA, et al. Clin Microbiol Rev. 2024 Jun 13;37(2):e0012123. doi: 10.1128/cmr.00121-23. Epub 2024 Mar 11. Clin Microbiol Rev. 2024. PMID: 38466110 Review. - The Weissella Genus: Clinically Treatable Bacteria with Antimicrobial/Probiotic Effects on Inflammation and Cancer.
Ahmed S, Singh S, Singh V, Roberts KD, Zaidi A, Rodriguez-Palacios A. Ahmed S, et al. Microorganisms. 2022 Dec 7;10(12):2427. doi: 10.3390/microorganisms10122427. Microorganisms. 2022. PMID: 36557680 Free PMC article. Review. - A case report of polymicrobial bacteremia with Weissella confusa and comparison of previous treatment for successful recovery with a review of the literature.
Spiegelhauer MR, Yusibova M, Rasmussen IKB, Fuglsang KA, Thomsen K, Andersen LP. Spiegelhauer MR, et al. Access Microbiol. 2020 Mar 26;2(5):acmi000119. doi: 10.1099/acmi.0.000119. eCollection 2020. Access Microbiol. 2020. PMID: 32974580 Free PMC article. - Identification and significance of Weissella species infections.
Kamboj K, Vasquez A, Balada-Llasat JM. Kamboj K, et al. Front Microbiol. 2015 Oct 31;6:1204. doi: 10.3389/fmicb.2015.01204. eCollection 2015. Front Microbiol. 2015. PMID: 26583007 Free PMC article. Review. - The genus Weissella: taxonomy, ecology and biotechnological potential.
Fusco V, Quero GM, Cho GS, Kabisch J, Meske D, Neve H, Bockelmann W, Franz CM. Fusco V, et al. Front Microbiol. 2015 Mar 17;6:155. doi: 10.3389/fmicb.2015.00155. eCollection 2015. Front Microbiol. 2015. PMID: 25852652 Free PMC article. Review.
References
- J Clin Microbiol. 1991 Oct;29(10):2335-7 - PubMed
- Antimicrob Agents Chemother. 1977 Sep;12(3):423-6 - PubMed
- J Clin Microbiol. 1991 May;29(5):1075-7 - PubMed
- Antimicrob Agents Chemother. 1991 Feb;35(2):215-9 - PubMed
- N Engl J Med. 1988 Jul 21;319(3):157-61 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous